Credit Suisse 12/04/2010 1 Outperform $40.50 12.6%
With 18 months worth of clinical data about the potential use of IVIG in Alzheimer's disease soon to be reported the broker suggests investing in the company gives a free option over this potential.
While a low case with respect to any blue sky is most likely in its view the broker sees enough value in the stock to retain its Outperform rating. Target unchanged at $40.50.
Target price is $40.50 Current Price is $36.08 Difference: $4.42
If CSL meets the Credit Suisse target it will return approximately 12% (excluding dividends, fees and charges).
Credit Suisse 12/04/2010 1 Outperform $40.50 12.6%With 18 months...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$307.80 |
Change
2.460(0.81%) |
Mkt cap ! $148.7B | |||
| Open | High | Low | Value | Volume |
| $305.41 | $308.69 | $304.34 | $158.2M | 514.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13 | $307.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $307.80 | 4197 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |